PACLITAXEL (paclitaxel protein-bound particles) by Cipla. Approved for microtubule inhibitor [epc]. First approved in 2025.
Drug data last refreshed 23h ago
Microtubule Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC
Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Worked on PACLITAXEL at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo